Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2026-05-19 16:05:02 ET · period of report 2026-05-15 · accession 0000875320-26-000226 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-05-19 16:05 | 2026-05-15 | VRTX | Bunnage Mark E. | EVP, CSO | S - Sale | $453.45 | -33 | 7,284 | -0.5% | -$15.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-15 | S | D | 33 | $453.45 | 7,284 | D | — | — | (F1) Transaction made pursuant to Dr. Bunnage's company approved trading plan under Rule 10b5-1, which was entered into on 11/26/2025. |